Ann Rheum Dis 1997;56:374-377 ( June )

Concise reports

Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis R Munro,^a E Morrison,^b A G McDonald,^a J A Hunter,^b R Madhok,^b H A Capell^a

^a Centre for Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow , ^b Gartnavel General Hospital, Glasgow

Correspondence to: Dr R Munro, Centre for Rheumatic Diseases, Royal Infirmary, Glasgow G4 0SF.

Accepted for publication 12 February 1997

OBJECTIVETo determine the effect of intramuscular gold and oral hydroxychloroquine(HCQ) on the lipid profile of patients with rheumatoid arthritis (RA).
METHODA prospective randomised clinical trial of 12 months' duration was performed in 100 RA patients. Data on clinical and laboratory parameters of disease activity, and fasting serum lipid samples was collected at baseline and at three monthly intervals over one year.
RESULTSThe expected second line response was seen with no significant difference in efficacy between the groups at 12 months. The HCQ group had a significant overall improvement in their lipid profile while there was a trend for lipid profiles in the gold group to worsen.
CONCLUSIONSHCQ is an effective second line agent that has beneficial effects on serum lipids. This should be taken into account when choosing a disease modifying anti-rheumatic drug in patients who suffer from RA and who have significant cardiovascular risk factors.

---

© 1997 by Annals of the Rheumatic Diseases
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Panoulas, V. F., Metsios, G. S., Pace, A. V., John, H., Treharne, G. J., Banks, M. J., Kitas, G. D. (2008). Hypertension in rheumatoid arthritis. Rheumatology (Oxford) 47: 1286-1298 [Abstract] [Full Text]  
• Peters, M J L, Vis, M, van Halm, V P, Wolbink, G J, Voskuyl, A E, Lems, W F, Dijkmans, B A C, Twisk, J W R, de Koning, M H M T, van de Stadt, R J, Nurmohamed, M T (2007). Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. Ann Rheum Dis 66: 958-961 [Abstract] [Full Text]  
• Sachet, J.C., Borba, E.F., Bonfa, E., Vinagre, C.G.C., Silva, V.M., Maranhao, R.C. (2007). Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients. Lupus 16: 273-278 [Abstract]  
• Hall, F. C., Dalbeth, N. (2005). Disease modification and cardiovascular risk reduction: two sides of the same coin?. Rheumatology (Oxford) 44: 1473-1482 [Abstract] [Full Text]  
• Barnes, E V, Narain, S, Naranjo, A, Shuster, J, Segal, M S, Sobel, E S, Armstrong, A E, Santiago, B E, Reeves, W H, Richards, H B (2005). High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus 14: 576-582 [Abstract]  
• Goodson, N. J., Silman, A. J., Pattison, D. J., Lunt, M., Bunn, D., Luben, R., Day, N., Khaw, K.-T., Symmons, D. P. M. (2004). Traditional cardiovascular risk factors measured prior to the onset of inflammatory polyarthritis. Rheumatology (Oxford) 43: 731-736 [Abstract] [Full Text]  
• Rajagopalan, S., Somers, E. C., Brook, R. D., Kehrer, C., Pfenninger, D., Lewis, E., Chakrabarti, A., Richardson, B. C., Shelden, E., McCune, W. J., Kaplan, M. J. (2004). Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood 103: 3677-3683 [Abstract] [Full Text]  
• Sattar, N., McCarey, D. W., Capell, H., McInnes, I. B. (2003). Explaining How "High-Grade" Systemic Inflammation Accelerates Vascular Risk in Rheumatoid Arthritis. Circulation 108: 2957-2963 [Abstract] [Full Text]  
• Kitas, G. D., Erb, N. (2003). Tackling ischaemic heart disease in rheumatoid arthritis. Rheumatology (Oxford) 42: 607-613 [Full Text]  
• Alkaabi, J. K., Ho, M., Levison, R., Pullar, T., Belch, J. J. F. (2003). Rheumatoid arthritis and macrovascular disease. Rheumatology (Oxford) 42: 292-297 [Abstract] [Full Text]  
• McEntegart, A., Capell, H. A., Creran, D., Rumley, A., Woodward, M., Lowe, G. D. O. (2001). Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford) 40: 640-644 [Abstract] [Full Text]  
• KAVANAUGH, A. (1998). Smoking, rheumatoid factors, and rheumatoid arthritis.. Ann Rheum Dis 57: 175-176 [Full Text]  
• SITUNAYAKE, R D, KITAS, G (1997). Dyslipidaemia and rheumatoid arthritis. Ann Rheum Dis 56: 341-342 [Full Text]